Wyeth’s Viviant “Approvable” For Prevention Of Postmenopausal Osteoporosis
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm continues to plan an additional submission this year for an osteoporosis treatment claim.
You may also be interested in...
Pfizer/Ligand’s Osteoporosis Drug Fablyn Gets Advisory Committee Review
Lasofoxifene beats out Wyeth’s Viviant for first advisory committee review of the competing next-generation SERMs.
Pfizer/Ligand’s Osteoporosis Drug Fablyn Gets Advisory Committee Review
Lasofoxifene beats out Wyeth’s Viviant for first advisory committee review of the competing next-generation SERMs.
Pfizer Files Lasofoxifene NDA For Treatment Of Osteoporosis
Selective estrogen receptor modulator now is called Fablyn rather than Oporia, a name under which it received two “not approvable” letters.